The clinical significance of PD-1 expression in circulating CD8+T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1+CD8+T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1+CD8+T-cell groups. The increased PD-1+CD8+T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1+CD8+T-cell group (PFS: 8.7 months vs. 6.1 months,p= 0.007; OS: 20.7 months vs. 10.8 months,p= 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months,p= 0.041). Multivariate analysis revealed that an increase in PD-1+CD8+T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1+CD8+T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.
PD-1在胃癌化疗患者循环CD8+T细胞中的临床意义尚未明确。因此，本研究旨在通过检测68例接受铂类化疗的晚期胃癌患者血液样本，探讨其预后价值。我们采用流式细胞术分析外周血单个核细胞，并评估其相关性。根据治疗第0天和第7天之间PD-1+CD8+T细胞频率的变化，将患者分为两组：PD-1+CD8+T细胞增加组与减少组。结果显示，增加组相比减少组具有更长的无进展生存期和总生存期（无进展生存期：8.7个月对比6.1个月，p=0.007；总生存期：20.7个月对比10.8个月，p=0.003）。两组间的平均缓解持续时间也存在显著差异（5.7个月对比2.5个月，p=0.041）。多变量分析表明PD-1+CD8+T细胞频率增加是独立的预后因素。我们得出结论：PD-1+CD8+T细胞频率的早期升高可作为晚期胃癌化疗患者预后良好和持续缓解的潜在预测指标。
肿瘤(癌症)患者之家